Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development

July 23, 2026
  • Alyssa Levin appointed to Board of Directors and as Chair of the Audit Committee
  • Clara Cambon-Thiebaud joins as VP, Regulatory Affairs
  • Céline Breda joins as VP, Chemistry, Manufacturing and Controls (CMC)

Read full press release here

< back

Recent posts

Cyllene Therapeutics (formerly known as EG 427) Raises €33 Million Series C Financing to Advance Clinical Development of EG110A and Pipeline Expansion
Cyllene Therapeutics (formerly known as EG 427) Raises €33 Million Series C Financing to Advance Clinical Development of EG110A and Pipeline Expansion

read more >

EG 427’s Clinical Data Showing Sustained Incontinence Episode Reduction with EG110A DNA Therapy Maintained at 6 Months Timepoint
EG 427’s Clinical Data Showing Sustained Incontinence Episode Reduction with EG110A DNA Therapy Maintained at 6 Months Timepoint

read more >

×

By clicking Consent, you accept the saving of all cookie data on your device. If you click Denied, only the data necessary for the website to function is saved. More information about cookies in the privacy policy.

settings Reject I agree
×

Essential Cookies

These cookies are necessary for the website to function and cannot be turned off. They are used, for example, to maintain the contents of the user's basket. You can set your browser to block these cookies, but then the website will not function prope

Always active

Analytical cookies

These cookies allow you to count visits and traffic sources. Thanks to these files, it is known which pages are more popular and how the website visitors navigate. All information these cookies collect is anonymous.